The Coronavirus massively highlighted a few distinct factors of the healthcare system. Primarily was the need for rapid drug development (in the form of various vaccines for Covid-19) and more importantly how important the identification of diseases at the earliest stages could not only reduce the chances of mortality for an individual but also allow for better quarantine measures to avoid epidemics which possess the potential to expand into future pandemics. With each passing year, technology has allowed us to delve deeper into the human anatomy & grow our existing…Read More
Speaker Spotlight – ‘Rachel Legmann ’ : 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference!
The 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference on the 20th & 21st of October 2022 aims to delve deep into defining trends & innovation withing the bioprocessing ecosystem around major domains like cell culture & bioproduction, downstream processing & continuous biomanufacturing and cell and gene therapy analytics. Just under 12 weeks remain till we go LIVE in Boston with over 100+ attendees, in-depth case studies, various networking sessions & keynote presentations from 15+ leading industry experts. We’re tremendously excited to hear the speakers’ ideas, findings & foresight into the future….Read More
Speaker Spotlight – ‘Joseph M. Roig’ : 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference!
Boston plays host to the 4th Annual MarketsandMarkets Next-Gen Bioprocessing Conference on the 20th & 21st of October 2022 and we’re literally counting down the days! With over 100+ attendees & in-depth case studies & keynote presentations from 15+ leading industry experts, the event promises to deliver a comprehensively enriching experience! As we keenly await to discover the speakers’ ideas, findings & foresight into the future of topics surrounding cell culture & bioproduction, downstream processing & continuous biomanufacturing and cell and gene therapy analytics, here’s a glimpse into what you…Read More
Expanding the Horizons of Healthcare Monitoring – Real World Data & Evidence!
The lifecycle of drug development, right from moment of conception till the time its approved for widespread usage, is an extremely long & complex one. The amount of data generated through trials or acquired from various points of collection, which is required to be analysed during this process is humongous. For a drug to be effective, the patient data which forms the foundation of its development, must closely reflect the conditions of the demographic or section of people it is intended for. This is where, Real World Data (RWD)…Read More
Precision Medicine – A Deep Dive into Personalized Therapy & Treatment
For the healthcare ecosystem across the world, the underlying purpose has always been to fight & eradicate illnesses in the shortest amount of time hence corelating with minimal pain, suffering or stress for the patients involved. Rapid technological advancements in the 21st century have meant that a humongous amount of clinical data and testing methods required to analyse it, exist during the same period. This has subsequently allowed for the emergence of ‘Precision Medicine’. Also referred to as Personalized Medicine, it is an innovative approach towards medicinal care.By utilizing the…Read More
Companion Diagnostics & Biomarkers – Paving the way for Personalized Medicine
Prior to and only enhanced by the pandemic, in vitro analysis of biological specimens like tissue samples or blood amongst others plays a huge role in guiding accurate diagnosis & subsequent therapy. When used in tandem with a specific therapeutic drug or medicine and relying on the presence or absence of a predictive biomarker, such IVD are known as Companion Diagnostics (CDx). A companion diagnostic is essentially a medical device while helps differentiate patients between responders & non responders with reference to a certain drug or therapy. For example, a…Read More
Developments & Challenges within the Single Cell Analysis Ecosystem
With just over a month till the MarketsandMarkets BioPharma Series kicks off in Boston on the 23rd & 24th of June 2022, we believed it would be apt to unveil a glimpse of the enriching insights our esteemed speakers shall be bringing to the tri-conference event. On the eve of our 3rd Annual MarketsandMarkets Single-Cell Analysis Conference, we sat down with Jun Wang, Associate Professor (Department of Biomedical Engineering) at Stony Brook University, New York who is also a keynote speaker at the conference. As part of the conversation, we…Read More
Immuno-Oncology : The Latest Frontier in Cancer Therapy
For as long as medicine has existed, cancers have ravaged humanity. The search for an eventual cure has been a tremendous & tireless pursuit, selflessly undertaken by doctors, researchers, scientists & the entire healthcare community. With each passing year and the availability of sophisticated technologies, their efforts continue to go from strength to strength, expanding our means to adequately cope, manage and possibly rebuff the disease which has so often reminded us of our mortality. Up until recently, Chemotherapy, Surgeries, Radiation & Targeted Drug therapies had been the go-to for…Read More
BIOSIMILARS: Origins & The Path Forward
Almost 7 years removed from the first FDA approved Biosimilar (Zarxio) in 2015, the US market for Biosimilars is projected to be highly beneficial over the next decade, for both pharmaceutical companies as well as patients, with RAND Corporation projecting estimated savings of over $54 Billion during this period. To truly comprehend such forecasts, a deeper understanding of what constitutes a ‘Biosimilar Drug’ is required. Essentially, the structure of a biosimilar is based on a pre-existing, approved drug known as a Biologic & possesses no significant clinical difference in safety,…Read More
Catch up with Matt Davis’ talk on “Neoantigen Targeted Cancer Immunotherapy in the Clinic” at Advance Genetic Sequencing Virtual Conference 2021
Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute. Marketsandmarkets took this opportunity to talk…Read More